Table 5.

Anti-checkpoint inhibitor drugs for NSCLC. * FDA-approved anti-checkpoint inhibitors.

Generic Name (Brand Name)	Mechanism	Ref.
Atezolizumab (Tecentriq®) *	PD-L1	[55,56]
Durvalumab (Imfinzi®) *	PD-L1	[55,56]
Nivolumab (Opdivo®) *	PD1	[55,56]
Pembrolizumab (Keytruda®) *	PD1	[55,56]
Ipilimumab (Yervoy®)	CTLA-4	[97,98]